Japan's R-zone likely to shrink in 1998
This article was originally published in Clinica
A reduction in the reasonable discounting rate for medical devices, or R-zone, will almost certainly be a primary objective of Japan's Ministry of Health and Welfare at the next major round of price revisions in April 1998. While prospects for market expansion in 1997 and 1998 continue to be positive, government plans to reform Japan's health insurance system and curb spending growth could have a negative impact on profitability, says the US Health Industry Manufacturers Association's Global Medical Technology Update.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.